Patents by Inventor Umar Maharoof

Umar Maharoof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
    Publication number: 20150105366
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 16, 2015
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings, William Moore Jones, Steven Goldberg
  • ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
    Publication number: 20150105369
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: KRISTI A. LEONARD, KENT BARBAY, JAMES P. EDWARDS, KEVIN D. KREUTTER, DAVID A. KUMMER, UMAR MAHAROOF, RACHEL NISHIMURA, MAUD URBANSKI, HARIHARAN VENKATESAN, AIHUA WANG, RONALD L. WOLIN, CRAIG R. WOODS, ANNE FOURIE, XIAOHUA XUE, MAXWELL D. CUMMINGS
  • HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
    Publication number: 20140107096
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: KRISTI A. LEONARD, KENT BARBAY, JAMES P. EDWARDS, KEVIN D. KREUTTER, DAVID A. KUMMER, UMAR MAHAROOF, RACHEL NISHIMURA, MAUD URBANSKI, HARIHARAN VENKATESAN, AIHUA WANG, RONALD L. WOLIN, CRAIG R. WOODS, ANNE FOURIE, XIAOHUA XUE
  • HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
    Publication number: 20140107097
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Taraneh Mirzadegan, Kelly Ganamet
  • METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
    Publication number: 20140107094
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Joan Pierce, Steven Goldberg, Anne Fourie, Xiaohua Xue
  • N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
    Patent number: 7795440
    Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: September 14, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Jr., Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen
  • N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
    Publication number: 20070142305
    Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell. proliferative disorders.
    Type: Application
    Filed: January 25, 2007
    Publication date: June 21, 2007
    Inventors: Chih Ho, Bengt Brunmark, Stuart Emanuel, Robert Galemmo, Dana Johnson, Donald Ludovici, Umar Maharoof, Jay Mei, Jan Sechler, Eric Strobel, Robert Tuman, Hwa Yen
  • N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
    Patent number: 7196110
    Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: March 27, 2007
    Assignee: Janssen Phamaceutica N.V.
    Inventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Jr., Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen
  • N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
    Publication number: 20040082639
    Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.
    Type: Application
    Filed: May 14, 2003
    Publication date: April 29, 2004
    Inventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen